The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center, Shanghai, People’s Republic of C...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/53eaad6d37924341a6e182feef22caef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:53eaad6d37924341a6e182feef22caef |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:53eaad6d37924341a6e182feef22caef2021-12-02T03:14:28ZThe effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects1179-1438https://doaj.org/article/53eaad6d37924341a6e182feef22caef2017-02-01T00:00:00Zhttps://www.dovepress.com/the-effect-of-apixaban-on-the-pharmacokinetics-of-digoxin-and-atenolol-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center, Shanghai, People’s Republic of China; 3Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 4Clinical Research, Intercept Pharmaceuticals, San Diego, CA, 5Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA Purpose: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug−drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin® (digoxin) and single-dose Tenormin® (atenolol) and the effects of single-dose atenolol on apixaban PK in healthy subjects were investigated in two Phase 1 studies. Patients and methods: The digoxin DDI study was an open-label, multidose, two-treatment, single-sequence study in which subjects received digoxin 0.25 mg q6h on day 1, then once daily on days 2–10, followed by apixaban 20 mg and digoxin 0.25 mg once daily on days 11–20. The atenolol DDI study was an open-label, single-dose, randomized, three-period, three-treatment, crossover study in which subjects received a single oral dose of apixaban 10 mg, atenolol 100 mg, or apixaban 10 mg plus atenolol 100 mg. The 90% confidence intervals (CIs) for the ratios of geometric means of peak plasma concentration (Cmax) and area under the concentration–time curve (AUCtau), with and without apixaban were calculated. Absence of effect was concluded if the point estimates and 90% CI were within the equivalence interval of 80%–125% (digoxin) or 70%–143% (atenolol). A similar analysis was performed to assess the effect of atenolol on apixaban. Results: Apixaban had no clinically relevant effect on the PK of either atenolol or digoxin: point estimates and 90% CI for both digoxin and atenolol Cmax and AUC were entirely within their respective no-effect intervals. Apixaban Cmax and AUCinf were slightly decreased (ie, 18% and 15% lower, respectively) following atenolol coadministration. No serious or major bleeding-related adverse events were reported during either study. Conclusion: Apixaban had no effect on the PK of digoxin and there was no clinically relevant interaction between apixaban and atenolol. Coadministration of digoxin or atenolol with apixaban in healthy subjects was generally well tolerated. Keywords: oral anticoagulant, factor Xa inhibitor, drug–drug interaction, Phase 1Frost CSong YYu ZWang JLee LSSchuster APollack ALaCreta FDove Medical Pressarticleoral anticoagulantfactor Xa inhibitordrug-drug interactionPhase 1Therapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 19-28 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
oral anticoagulant factor Xa inhibitor drug-drug interaction Phase 1 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
oral anticoagulant factor Xa inhibitor drug-drug interaction Phase 1 Therapeutics. Pharmacology RM1-950 Frost C Song Y Yu Z Wang J Lee LS Schuster A Pollack A LaCreta F The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| description |
Charles Frost,1 Yan Song,1 Zhigang Yu,2 Jessie Wang,3 Lois S Lee,4 Alan Schuster,5 Allyson Pollack,1 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2Medical Sciences, Amgen Asia R&D Center, Shanghai, People’s Republic of China; 3Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 4Clinical Research, Intercept Pharmaceuticals, San Diego, CA, 5Bioanalytical Sciences, Bristol-Myers Squibb, Princeton, NJ, USA Purpose: Apixaban is often coadministered with treatments for cardiovascular comorbidities, which may lead to unintended drug−drug interactions (DDIs). The effects of apixaban on pharmacokinetics (PK) of multidose Lanoxin® (digoxin) and single-dose Tenormin® (atenolol) and the effects of single-dose atenolol on apixaban PK in healthy subjects were investigated in two Phase 1 studies. Patients and methods: The digoxin DDI study was an open-label, multidose, two-treatment, single-sequence study in which subjects received digoxin 0.25 mg q6h on day 1, then once daily on days 2–10, followed by apixaban 20 mg and digoxin 0.25 mg once daily on days 11–20. The atenolol DDI study was an open-label, single-dose, randomized, three-period, three-treatment, crossover study in which subjects received a single oral dose of apixaban 10 mg, atenolol 100 mg, or apixaban 10 mg plus atenolol 100 mg. The 90% confidence intervals (CIs) for the ratios of geometric means of peak plasma concentration (Cmax) and area under the concentration–time curve (AUCtau), with and without apixaban were calculated. Absence of effect was concluded if the point estimates and 90% CI were within the equivalence interval of 80%–125% (digoxin) or 70%–143% (atenolol). A similar analysis was performed to assess the effect of atenolol on apixaban. Results: Apixaban had no clinically relevant effect on the PK of either atenolol or digoxin: point estimates and 90% CI for both digoxin and atenolol Cmax and AUC were entirely within their respective no-effect intervals. Apixaban Cmax and AUCinf were slightly decreased (ie, 18% and 15% lower, respectively) following atenolol coadministration. No serious or major bleeding-related adverse events were reported during either study. Conclusion: Apixaban had no effect on the PK of digoxin and there was no clinically relevant interaction between apixaban and atenolol. Coadministration of digoxin or atenolol with apixaban in healthy subjects was generally well tolerated. Keywords: oral anticoagulant, factor Xa inhibitor, drug–drug interaction, Phase 1 |
| format |
article |
| author |
Frost C Song Y Yu Z Wang J Lee LS Schuster A Pollack A LaCreta F |
| author_facet |
Frost C Song Y Yu Z Wang J Lee LS Schuster A Pollack A LaCreta F |
| author_sort |
Frost C |
| title |
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| title_short |
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| title_full |
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| title_fullStr |
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| title_full_unstemmed |
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| title_sort |
effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/53eaad6d37924341a6e182feef22caef |
| work_keys_str_mv |
AT frostc theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT songy theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT yuz theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT wangj theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT leels theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT schustera theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT pollacka theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT lacretaf theeffectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT frostc effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT songy effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT yuz effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT wangj effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT leels effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT schustera effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT pollacka effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects AT lacretaf effectofapixabanonthepharmacokineticsofdigoxinandatenololinhealthysubjects |
| _version_ |
1718401853287301120 |